Saturday 17 October 2026
Export TRDA’s income statement to Excel — free account
Entrada Therapeutics, Inc.
TRDA Healthcare Biotechnology
Entrada Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $25.4 million, down 87.9% from fiscal 2024. In the quarter to June 2026, revenue fell 54.0%, EPS grew 2.88% and free cash flow fell 9.10%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
4.36
0.42
−8.79%
Follow TRDA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
66.31 | 92.01 | 16.73 | 3.91 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(9.57) | (12.66) | (13.21) | (8.49) | |
P/B ratio |
1.33 | 1.95 | 1.39 | 0.71 | |
Price to Tangible BV |
1.33 | 1.95 | 1.39 | 0.71 | |
EV/Sales |
18.73 | 47.60 | 5.07 | (1.40) | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.70 | |
EV/Operating CF |
(0.65) | (2.07) | (1.00) | 0.68 | |
EV/FCF |
(0.65) | (2.07) | (1.00) | 0.67 | |
Quick Ratio |
10.47 | 13.32 | 12.17 | 13.66 | |
Current Ratio |
10.89 | 13.90 | 12.53 | 14.08 | |
Net Debt/EBITDA |
5.00 | 6.06 | 7.06 | 7.02 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.01 | 0.06 | 0.13 | |
Operating CF/Net income |
0.76 | 1.05 | 0.82 | 0.64 | |
Capex/Depreciation |
(0.03) | (0.17) | 0.82 | 0.35 | |
Research and Development Expense of Revenue |
3,938.64% | 3,777.60% | 2,614.09% | 2,376.77% | |
Selling, General and Administrative Expense of Revenue |
1,168.37% | 1,157.03% | 735.18% | 638.41% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
573.50% | 542.17% | 335.49% | 316.98% | |
Graham Net Nets |
0.54 | 0.38 | 0.55 | 1.11 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(53.80%) | (31.62%) | (33.66%) | (42.93%) | |
Free Cash Flow Yield |
(43.23%) | (24.93%) | (30.46%) | (53.97%) | |
Revenue per Share |
0.02 | 0.02 | 0.03 | 0.04 | |
Operating CF per Share |
(0.77) | (1.00) | (0.78) | (0.68) | |
Capex per Share |
0.00 | 0.00 | 0.01 | 0.00 | |
Free Cash Flow per Share |
(0.77) | (1.00) | (0.77) | (0.68) | |
Cash per Share |
5.28 | 6.09 | 7.16 | 7.88 | |
Shareholders Equity per Share |
5.53 | 6.47 | 7.40 | 8.22 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.53 | 6.47 | 7.40 | 8.22 | |
Free Cash Flow |
(32.47) | (41.74) | (32.00) | (28.14) | |
Working Capital |
211.33 | 247.68 | 281.80 | 314.24 | |
Capital Expenditures |
(0.01) | (0.04) | 0.21 | 0.17 | |
Net Current Asset Value |
167.24 | 202.21 | 235.01 | 266.08 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.71 | |
Capex to Sales |
0.01 | 0.05 | (0.16) | (0.11) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.00 | 1.42 | 2.43 | 1.90 | |
Average Payables |
2.80 | 2.56 | 3.27 | 2.23 | |
Average Assets |
373.83 | 411.00 | 451.85 | 483.74 | |
Average Common Equity |
306.46 | 344.06 | 367.41 | 381.58 |
Columns are period end dates